JP4764168B2 - アミノインダゾール誘導体及びキナーゼ阻害剤としてのその使用 - Google Patents
アミノインダゾール誘導体及びキナーゼ阻害剤としてのその使用 Download PDFInfo
- Publication number
- JP4764168B2 JP4764168B2 JP2005512867A JP2005512867A JP4764168B2 JP 4764168 B2 JP4764168 B2 JP 4764168B2 JP 2005512867 A JP2005512867 A JP 2005512867A JP 2005512867 A JP2005512867 A JP 2005512867A JP 4764168 B2 JP4764168 B2 JP 4764168B2
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- indazol
- alkyl
- chloro
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- YDTDKKULPWTHRV-UHFFFAOYSA-N 1H-indazol-3-amine Chemical class C1=CC=C2C(N)=NNC2=C1 YDTDKKULPWTHRV-UHFFFAOYSA-N 0.000 title description 10
- 229940043355 kinase inhibitor Drugs 0.000 title description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 title description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 112
- -1 6,7-difluoro-5-phenyl-1H-indazol-3-yl Chemical group 0.000 claims description 73
- 229910052736 halogen Inorganic materials 0.000 claims description 56
- 150000002367 halogens Chemical class 0.000 claims description 56
- 239000000203 mixture Substances 0.000 claims description 38
- 150000003839 salts Chemical class 0.000 claims description 27
- 125000000623 heterocyclic group Chemical group 0.000 claims description 26
- 150000001875 compounds Chemical class 0.000 claims description 25
- 239000000047 product Substances 0.000 claims description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 15
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 5
- 150000001408 amides Chemical class 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- ZTYQJXMWHOAAEA-UHFFFAOYSA-N 6,7-difluoro-5-phenyl-1h-indazol-3-amine Chemical compound C1=C2C(N)=NNC2=C(F)C(F)=C1C1=CC=CC=C1 ZTYQJXMWHOAAEA-UHFFFAOYSA-N 0.000 claims description 2
- QAJULVBVVYKOIK-UHFFFAOYSA-N N1(CCCC1)C(=O)O.FC1=C(C=C2C(=NNC2=C1F)NC(=O)N1CCCCC1)C1=CC=CC=C1 Chemical compound N1(CCCC1)C(=O)O.FC1=C(C=C2C(=NNC2=C1F)NC(=O)N1CCCCC1)C1=CC=CC=C1 QAJULVBVVYKOIK-UHFFFAOYSA-N 0.000 claims description 2
- 239000013067 intermediate product Substances 0.000 claims description 2
- XQNSNRRJMMZBTC-UHFFFAOYSA-N 1-(6,7-difluoro-5-phenyl-1h-indazol-3-yl)-3-[3-(4-methylpiperazin-1-yl)propyl]urea Chemical compound C1CN(C)CCN1CCCNC(=O)NC1=NNC2=C(F)C(F)=C(C=3C=CC=CC=3)C=C12 XQNSNRRJMMZBTC-UHFFFAOYSA-N 0.000 claims 1
- JSGISZCYCLUJLZ-UHFFFAOYSA-N 6,7-difluoro-5-phenyl-1-(2-trimethylsilylethoxymethyl)indazol-3-amine N-[6,7-difluoro-5-phenyl-1-(2-trimethylsilylethoxymethyl)indazol-3-yl]butanamide Chemical compound FC1=C(C=C2C(=NN(C2=C1F)COCC[Si](C)(C)C)N)C1=CC=CC=C1.C(CCC)(=O)NC1=NN(C2=C(C(=C(C=C12)C1=CC=CC=C1)F)F)COCC[Si](C)(C)C JSGISZCYCLUJLZ-UHFFFAOYSA-N 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 description 97
- 125000001072 heteroaryl group Chemical group 0.000 description 86
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 50
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 50
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 39
- 125000001424 substituent group Chemical group 0.000 description 38
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 36
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- 125000003342 alkenyl group Chemical group 0.000 description 31
- 125000000304 alkynyl group Chemical group 0.000 description 31
- 125000000753 cycloalkyl group Chemical group 0.000 description 31
- 229910052757 nitrogen Inorganic materials 0.000 description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 23
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 125000003545 alkoxy group Chemical group 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 18
- 125000005592 polycycloalkyl group Polymers 0.000 description 18
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 14
- 230000002829 reductive effect Effects 0.000 description 14
- 125000005842 heteroatom Chemical group 0.000 description 13
- 229910052760 oxygen Inorganic materials 0.000 description 13
- 229910052717 sulfur Inorganic materials 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 125000004043 oxo group Chemical group O=* 0.000 description 12
- 238000010992 reflux Methods 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 10
- 239000000243 solution Substances 0.000 description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- 230000008878 coupling Effects 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- 229910052763 palladium Inorganic materials 0.000 description 8
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 229910052786 argon Inorganic materials 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 7
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 7
- 125000005469 ethylenyl group Chemical group 0.000 description 7
- 125000002883 imidazolyl group Chemical group 0.000 description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 7
- 125000002971 oxazolyl group Chemical group 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 125000000335 thiazolyl group Chemical group 0.000 description 7
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 238000001819 mass spectrum Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 6
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 5
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 239000012429 reaction media Substances 0.000 description 5
- GETTZEONDQJALK-UHFFFAOYSA-N (trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1 GETTZEONDQJALK-UHFFFAOYSA-N 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 4
- 208000007530 Essential hypertension Diseases 0.000 description 4
- 201000011240 Frontotemporal dementia Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 206010061598 Immunodeficiency Diseases 0.000 description 4
- 208000029462 Immunodeficiency disease Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 210000004227 basal ganglia Anatomy 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 230000001054 cortical effect Effects 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000007813 immunodeficiency Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 208000033808 peripheral neuropathy Diseases 0.000 description 4
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 230000001936 parietal effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 102000013498 tau Proteins Human genes 0.000 description 3
- 108010026424 tau Proteins Proteins 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 2
- VRJHQPZVIGNGMX-UHFFFAOYSA-N 4-piperidinone Chemical compound O=C1CCNCC1 VRJHQPZVIGNGMX-UHFFFAOYSA-N 0.000 description 2
- SVCNLECORJCINH-UHFFFAOYSA-N 6,7-difluoro-1h-indazol-3-amine Chemical compound FC1=CC=C2C(N)=NNC2=C1F SVCNLECORJCINH-UHFFFAOYSA-N 0.000 description 2
- HLAUZGMPWBIZCZ-UHFFFAOYSA-N 6,7-difluoro-5-phenyl-1-(2-trimethylsilylethoxymethyl)indazol-3-amine Chemical compound FC=1C(F)=C2N(COCC[Si](C)(C)C)N=C(N)C2=CC=1C1=CC=CC=C1 HLAUZGMPWBIZCZ-UHFFFAOYSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 208000024571 Pick disease Diseases 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000004703 alkoxides Chemical class 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000016097 disease of metabolism Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- SWTUOJJTEFCXIH-UHFFFAOYSA-N ethyl n-(6,7-difluoro-5-phenyl-1h-indazol-3-yl)carbamate Chemical compound C1=C2C(NC(=O)OCC)=NNC2=C(F)C(F)=C1C1=CC=CC=C1 SWTUOJJTEFCXIH-UHFFFAOYSA-N 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 125000004404 heteroalkyl group Chemical group 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- PEIFULAAYQSODW-UHFFFAOYSA-N n-(6,7-difluoro-1h-indazol-3-yl)butanamide Chemical compound FC1=CC=C2C(NC(=O)CCC)=NNC2=C1F PEIFULAAYQSODW-UHFFFAOYSA-N 0.000 description 2
- VEYZZNXEUAWJKB-UHFFFAOYSA-N n-(6,7-difluoro-5-phenyl-1h-indazol-3-yl)piperidine-1-carboxamide Chemical compound C1=2C=C(C=3C=CC=CC=3)C(F)=C(F)C=2NN=C1NC(=O)N1CCCCC1 VEYZZNXEUAWJKB-UHFFFAOYSA-N 0.000 description 2
- MVVQBLQFJPBWQK-UHFFFAOYSA-N n-(6,7-difluoro-5-phenyl-1h-indazol-3-yl)pyrrolidine-1-carboxamide Chemical compound C1=2C=C(C=3C=CC=CC=3)C(F)=C(F)C=2NN=C1NC(=O)N1CCCC1 MVVQBLQFJPBWQK-UHFFFAOYSA-N 0.000 description 2
- QYUOATCXTVZREV-UHFFFAOYSA-N n-[5-bromo-6,7-difluoro-1-(2-trimethylsilylethoxymethyl)indazol-3-yl]butanamide Chemical compound FC1=C(Br)C=C2C(NC(=O)CCC)=NN(COCC[Si](C)(C)C)C2=C1F QYUOATCXTVZREV-UHFFFAOYSA-N 0.000 description 2
- CBJBYMVEYUJAOZ-UHFFFAOYSA-N n-[6,7-difluoro-5-phenyl-1-(2-trimethylsilylethoxymethyl)indazol-3-yl]pyrrolidine-1-carboxamide Chemical compound C12=CC(C=3C=CC=CC=3)=C(F)C(F)=C2N(COCC[Si](C)(C)C)N=C1NC(=O)N1CCCC1 CBJBYMVEYUJAOZ-UHFFFAOYSA-N 0.000 description 2
- 125000004676 n-butylcarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 150000003141 primary amines Chemical group 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 230000009822 protein phosphorylation Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000001119 stannous chloride Substances 0.000 description 2
- 235000011150 stannous chloride Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000006277 sulfonation reaction Methods 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- DGDHPCNVKMESMD-UHFFFAOYSA-N (6,7-difluoro-5-phenyl-1h-indazol-3-yl)carbamic acid Chemical compound C1=C2C(NC(=O)O)=NNC2=C(F)C(F)=C1C1=CC=CC=C1 DGDHPCNVKMESMD-UHFFFAOYSA-N 0.000 description 1
- ZHHLUSBLFDJQBZ-UHFFFAOYSA-N (6-chloro-7-hydroxy-5-phenyl-1H-indazol-3-yl)urea (6-chloro-7-methoxy-5-phenyl-1H-indazol-3-yl)urea [6-chloro-5-phenyl-7-(trifluoromethyl)-1H-indazol-3-yl]urea Chemical compound ClC1=C(C=C2C(=NNC2=C1C(F)(F)F)NC(=O)N)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1OC)NC(=O)N)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1O)NC(=O)N)C1=CC=CC=C1 ZHHLUSBLFDJQBZ-UHFFFAOYSA-N 0.000 description 1
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- KWRBZNZBCNVAIA-UHFFFAOYSA-N 1,4-difluoroindazol-3-amine Chemical compound FC1=C2C(=NN(C2=CC=C1)F)N KWRBZNZBCNVAIA-UHFFFAOYSA-N 0.000 description 1
- JICVPALOSNYWEZ-UHFFFAOYSA-N 1-(6-chloro-7-fluoro-5-phenyl-1h-indazol-3-yl)-3-(4-fluorophenyl)urea Chemical compound C1=CC(F)=CC=C1NC(=O)NC1=NNC2=C(F)C(Cl)=C(C=3C=CC=CC=3)C=C12 JICVPALOSNYWEZ-UHFFFAOYSA-N 0.000 description 1
- XJEAYGMCLVQAOD-UHFFFAOYSA-N 1-(6-chloro-7-fluoro-5-phenyl-1h-indazol-3-yl)-3-(4-methylphenyl)urea Chemical compound C1=CC(C)=CC=C1NC(=O)NC1=NNC2=C(F)C(Cl)=C(C=3C=CC=CC=3)C=C12 XJEAYGMCLVQAOD-UHFFFAOYSA-N 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 1
- MXPKWWZRGFOGRZ-UHFFFAOYSA-N 1-benzyl-3-(6-chloro-7-fluoro-5-phenyl-1h-indazol-3-yl)urea Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NC(=O)NCC1=CC=CC=C1 MXPKWWZRGFOGRZ-UHFFFAOYSA-N 0.000 description 1
- WGSXKYXKAARAKD-UHFFFAOYSA-N 1-fluoro-3-isocyanato-5-(trifluoromethyl)benzene Chemical group FC1=CC(N=C=O)=CC(C(F)(F)F)=C1 WGSXKYXKAARAKD-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
- GDHXJNRAJRCGMX-UHFFFAOYSA-N 2-fluorobenzonitrile Chemical compound FC1=CC=CC=C1C#N GDHXJNRAJRCGMX-UHFFFAOYSA-N 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- AEKVBBNGWBBYLL-UHFFFAOYSA-N 4-fluorobenzonitrile Chemical compound FC1=CC=C(C#N)C=C1 AEKVBBNGWBBYLL-UHFFFAOYSA-N 0.000 description 1
- ZCUSNQPYUNLATP-UHFFFAOYSA-N 5-phenyl-1h-indazol-3-amine Chemical compound C1=C2C(N)=NNC2=CC=C1C1=CC=CC=C1 ZCUSNQPYUNLATP-UHFFFAOYSA-N 0.000 description 1
- SMPISFVMHOVUTG-UHFFFAOYSA-N 6-chloro-7-fluoro-5-phenyl-n-[4-(trifluoromethyl)phenyl]-1h-indazol-3-amine Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NC1=CC=C(C(F)(F)F)C=C1 SMPISFVMHOVUTG-UHFFFAOYSA-N 0.000 description 1
- SADVHEXWFHVSGZ-UHFFFAOYSA-N 6-chloro-7-fluoro-5-phenyl-n-[[3-(trifluoromethyl)phenyl]methyl]-1h-indazol-3-amine Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NCC1=CC=CC(C(F)(F)F)=C1 SADVHEXWFHVSGZ-UHFFFAOYSA-N 0.000 description 1
- SPYHINSEACAYOX-UHFFFAOYSA-N 6-chloro-7-fluoro-n-(2-morpholin-4-ylethyl)-5-phenyl-1h-indazol-3-amine Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NCCN1CCOCC1 SPYHINSEACAYOX-UHFFFAOYSA-N 0.000 description 1
- LRVGEODPBQUEAY-UHFFFAOYSA-N 6-chloro-7-fluoro-n-(4-fluorophenyl)-5-phenyl-1h-indazol-3-amine;6-chloro-7-fluoro-5-phenyl-n-[3-(trifluoromethyl)phenyl]-1h-indazol-3-amine Chemical compound C1=CC(F)=CC=C1NC1=NNC2=C(F)C(Cl)=C(C=3C=CC=CC=3)C=C12.N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NC1=CC=CC(C(F)(F)F)=C1 LRVGEODPBQUEAY-UHFFFAOYSA-N 0.000 description 1
- YAGWFLLSABAFDE-UHFFFAOYSA-N 6-chloro-7-fluoro-n-[(2,3,4,5,6-pentafluorophenyl)methyl]-5-phenyl-1h-indazol-3-amine Chemical compound FC1=C(F)C(F)=C(F)C(F)=C1CNC1=NNC2=C(F)C(Cl)=C(C=3C=CC=CC=3)C=C12 YAGWFLLSABAFDE-UHFFFAOYSA-N 0.000 description 1
- WHTVTKUNBNJULC-UHFFFAOYSA-N 6-chloro-7-fluoro-n-[(3-methoxyphenyl)methyl]-5-phenyl-1h-indazol-3-amine Chemical compound COC1=CC=CC(CNC=2C3=CC(=C(Cl)C(F)=C3NN=2)C=2C=CC=CC=2)=C1 WHTVTKUNBNJULC-UHFFFAOYSA-N 0.000 description 1
- PAHCXFWKWFTIKL-UHFFFAOYSA-N 6-chloro-n-(cyclopropylmethyl)-7-fluoro-5-phenyl-1h-indazol-3-amine;6-chloro-7-fluoro-5-phenyl-n-(3-phenylpropyl)-1h-indazol-3-amine Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NCC1CC1.N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NCCCC1=CC=CC=C1 PAHCXFWKWFTIKL-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000208223 Anacardiaceae Species 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- JUFIGQSJJAAXNO-UHFFFAOYSA-N C1(=CC=CC=C1)S(=O)(=O)NC1=NNC2=C(C(=C(C=C12)C1=CC=CC=C1)Cl)F.ClC1=C(C=C2C(=NNC2=C1F)NS(=O)(=O)C=1SC=CC1)C1=CC=CC=C1 Chemical compound C1(=CC=CC=C1)S(=O)(=O)NC1=NNC2=C(C(=C(C=C12)C1=CC=CC=C1)Cl)F.ClC1=C(C=C2C(=NNC2=C1F)NS(=O)(=O)C=1SC=CC1)C1=CC=CC=C1 JUFIGQSJJAAXNO-UHFFFAOYSA-N 0.000 description 1
- GTDMJKDDIVJWTM-UHFFFAOYSA-N CN(C=O)C.FC1=CC=C2C(=NN(C2=C1F)COCC[Si](C)(C)C)NC(CCC)=O Chemical compound CN(C=O)C.FC1=CC=C2C(=NN(C2=C1F)COCC[Si](C)(C)C)NC(CCC)=O GTDMJKDDIVJWTM-UHFFFAOYSA-N 0.000 description 1
- OOWYJOSSOHTSJP-UHFFFAOYSA-N CN1CCN(CC1)CCCNC(N)=O.CN1CCN(CC1)CCCN Chemical compound CN1CCN(CC1)CCCNC(N)=O.CN1CCN(CC1)CCCN OOWYJOSSOHTSJP-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- CEEUMEIWLIIATG-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1C#C)NC(=O)N)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1N(C)C)NC(=O)N)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1N)NC(=O)N)C1=CC=CC=C1 Chemical compound ClC1=C(C=C2C(=NNC2=C1C#C)NC(=O)N)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1N(C)C)NC(=O)N)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1N)NC(=O)N)C1=CC=CC=C1 CEEUMEIWLIIATG-UHFFFAOYSA-N 0.000 description 1
- JZIWEJQWRZWZGD-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1C1CC1)NC(=O)N)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1C#N)NC(=O)N)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1C)NC(=O)N)C1=CC=CC=C1 Chemical compound ClC1=C(C=C2C(=NNC2=C1C1CC1)NC(=O)N)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1C#N)NC(=O)N)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1C)NC(=O)N)C1=CC=CC=C1 JZIWEJQWRZWZGD-UHFFFAOYSA-N 0.000 description 1
- BLGMIDNBBYLRMJ-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)N)C1=C(C=CC=C1)CC=1OC(=CC1)C1=CC=C(C=C1)Cl Chemical compound ClC1=C(C=C2C(=NNC2=C1F)N)C1=C(C=CC=C1)CC=1OC(=CC1)C1=CC=C(C=C1)Cl BLGMIDNBBYLRMJ-UHFFFAOYSA-N 0.000 description 1
- MXLJTEIATIZNQH-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NC(=O)NC1=CC=C(C=C1)Cl)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NC(=O)NCCC)C1=CC=CC=C1 Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NC(=O)NC1=CC=C(C=C1)Cl)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NC(=O)NCCC)C1=CC=CC=C1 MXLJTEIATIZNQH-UHFFFAOYSA-N 0.000 description 1
- XOLGPJIPNHLZJL-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NC(=O)NC1CCCCC1)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NC(=O)NC1=CC=C(C=C1)OC)C1=CC=CC=C1 Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NC(=O)NC1CCCCC1)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NC(=O)NC1=CC=C(C=C1)OC)C1=CC=CC=C1 XOLGPJIPNHLZJL-UHFFFAOYSA-N 0.000 description 1
- DSTASFCKHZNPBO-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NC(=O)NCC=C)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NC(=O)NC1=CC(=CC(=C1)Cl)Cl)C1=CC=CC=C1 Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NC(=O)NCC=C)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NC(=O)NC1=CC(=CC(=C1)Cl)Cl)C1=CC=CC=C1 DSTASFCKHZNPBO-UHFFFAOYSA-N 0.000 description 1
- LMPUXEAEVJCRFP-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NC1=C(C=C(C=C1F)F)F)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NC1=C(C(=CC(=C1F)F)F)F)C1=CC=CC=C1 Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NC1=C(C=C(C=C1F)F)F)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NC1=C(C(=CC(=C1F)F)F)F)C1=CC=CC=C1 LMPUXEAEVJCRFP-UHFFFAOYSA-N 0.000 description 1
- VQTPHPZXEMHZGU-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NC1=CC(=C(C=C1)F)F)C1=CC=CC=C1.FC1=C(C(=C(C(=C1N1N=C(C2=CC(=CC=C12)C1=CC=CC=C1)N)F)F)F)F Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NC1=CC(=C(C=C1)F)F)C1=CC=CC=C1.FC1=C(C(=C(C(=C1N1N=C(C2=CC(=CC=C12)C1=CC=CC=C1)N)F)F)F)F VQTPHPZXEMHZGU-UHFFFAOYSA-N 0.000 description 1
- SKYKKMVNHJEGEX-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NC1=CC(=CC=C1)OC)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NC1=CC(=CC=C1)[N+](=O)[O-])C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NC1=CC=C(C=C1)[N+](=O)[O-])C1=CC=CC=C1 Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NC1=CC(=CC=C1)OC)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NC1=CC(=CC=C1)[N+](=O)[O-])C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NC1=CC=C(C=C1)[N+](=O)[O-])C1=CC=CC=C1 SKYKKMVNHJEGEX-UHFFFAOYSA-N 0.000 description 1
- CYZGPRHIDPNKLW-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NCC1=CC(=CC=C1)OC1=CC=C(C=C1)C)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCC1=CC=C(C=C1)F)C1=CC=CC=C1 Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NCC1=CC(=CC=C1)OC1=CC=C(C=C1)C)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCC1=CC=C(C=C1)F)C1=CC=CC=C1 CYZGPRHIDPNKLW-UHFFFAOYSA-N 0.000 description 1
- GTQGSLGYVWFVSK-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NCC1=CSC=C1)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCC1=CC=C(O1)C1=CC=C(C=C1)S(=O)(=O)N)C1=CC=CC=C1 Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NCC1=CSC=C1)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCC1=CC=C(O1)C1=CC=C(C=C1)S(=O)(=O)N)C1=CC=CC=C1 GTQGSLGYVWFVSK-UHFFFAOYSA-N 0.000 description 1
- BJSHMUUGLPJWFZ-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NCC=1N=C(NC1)C)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCC1=NNC=C1)C1=CC=CC=C1 Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NCC=1N=C(NC1)C)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCC1=NNC=C1)C1=CC=CC=C1 BJSHMUUGLPJWFZ-UHFFFAOYSA-N 0.000 description 1
- RULVROHSLZOZEB-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NCC=1N=C(NC1)C1=CC=CC=C1)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCC=1C(=NN(C1C)C1=CC=CC=C1)C)C1=CC=CC=C1 Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NCC=1N=C(NC1)C1=CC=CC=C1)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCC=1C(=NN(C1C)C1=CC=CC=C1)C)C1=CC=CC=C1 RULVROHSLZOZEB-UHFFFAOYSA-N 0.000 description 1
- ZYEKLSLPOGVUHD-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NCC=1NC(=C(N1)C(=O)O)SC)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCC=1N=C(NC1)C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NCC=1NC(=C(N1)C(=O)O)SC)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCC=1N=C(NC1)C1=CC=CC=C1)C1=CC=CC=C1 ZYEKLSLPOGVUHD-UHFFFAOYSA-N 0.000 description 1
- NIQCISFQEWGSGE-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NCCC(C)(C)C)C1=CC=CC=C1.C12C(CC(C=C1)C2)CNC2=NNC1=C(C(=C(C=C21)C2=CC=CC=C2)Cl)F Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NCCC(C)(C)C)C1=CC=CC=C1.C12C(CC(C=C1)C2)CNC2=NNC1=C(C(=C(C=C21)C2=CC=CC=C2)Cl)F NIQCISFQEWGSGE-UHFFFAOYSA-N 0.000 description 1
- MFSGZHBYWIJBTQ-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NCCC)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCC1CCCCC1)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCCC1=CC=CC=C1)C1=CC=CC=C1 Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NCCC)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCC1CCCCC1)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCCC1=CC=CC=C1)C1=CC=CC=C1 MFSGZHBYWIJBTQ-UHFFFAOYSA-N 0.000 description 1
- HHRBFMRRZCBBCM-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NCCCC(F)(F)F)C1=CC=CC=C1.O.ClC1=C(C=C2C(=NNC2=C1F)NCC(C(C(F)(F)F)(F)F)(F)F)C1=CC=CC=C1 Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NCCCC(F)(F)F)C1=CC=CC=C1.O.ClC1=C(C=C2C(=NNC2=C1F)NCC(C(C(F)(F)F)(F)F)(F)F)C1=CC=CC=C1 HHRBFMRRZCBBCM-UHFFFAOYSA-N 0.000 description 1
- OALIUNOOWANTHI-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NCCCSC)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCC1CCCC1)C1=CC=CC=C1 Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NCCCSC)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCC1CCCC1)C1=CC=CC=C1 OALIUNOOWANTHI-UHFFFAOYSA-N 0.000 description 1
- QBMCMGDIJKNMOQ-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NCCN1CCCCC1)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCC=1OC(=CC1)C1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1 Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NCCN1CCCCC1)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NCC=1OC(=CC1)C1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1 QBMCMGDIJKNMOQ-UHFFFAOYSA-N 0.000 description 1
- XTOHJCIZETZHOA-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NN1CC=CC=C1)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NC1=CC=CC=C1)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NC1=CC=C(C=C1)OC)C1=CC=CC=C1 Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NN1CC=CC=C1)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NC1=CC=CC=C1)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NC1=CC=C(C=C1)OC)C1=CC=CC=C1 XTOHJCIZETZHOA-UHFFFAOYSA-N 0.000 description 1
- GWTBCTPRFMQUAC-UHFFFAOYSA-N ClC1=C(C=C2C(=NNC2=C1F)NS(=O)(=O)CC1=CC=C(C=C1)C)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NS(=O)(=O)C1=CC=C(C=C1)NC(C)=O)C1=CC=CC=C1.C1(=CC=CC=C1)S(=O)(=O)N Chemical compound ClC1=C(C=C2C(=NNC2=C1F)NS(=O)(=O)CC1=CC=C(C=C1)C)C1=CC=CC=C1.ClC1=C(C=C2C(=NNC2=C1F)NS(=O)(=O)C1=CC=C(C=C1)NC(C)=O)C1=CC=CC=C1.C1(=CC=CC=C1)S(=O)(=O)N GWTBCTPRFMQUAC-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- CWVXOFSTTOTUFR-UHFFFAOYSA-N FC1=C(C=C2C(=NN(C2=C1F)COCC[Si](C)(C)C)N(C(CCC)=O)C1=C(C=CC=C1)B(O)O)C1=CC=CC=C1 Chemical compound FC1=C(C=C2C(=NN(C2=C1F)COCC[Si](C)(C)C)N(C(CCC)=O)C1=C(C=CC=C1)B(O)O)C1=CC=CC=C1 CWVXOFSTTOTUFR-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- FAOHOWQOSJNHLN-UHFFFAOYSA-N N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-6-chloro-7-fluoro-5-phenyl-1H-indazol-3-amine 6-chloro-7-fluoro-N-(2,2,3,3,4,4,4-heptafluorobutyl)-5-phenyl-1H-indazol-3-amine Chemical compound C=1C=2C(NCC(F)(F)C(F)(F)C(F)(F)F)=NNC=2C(F)=C(Cl)C=1C1=CC=CC=C1.N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NCC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 FAOHOWQOSJNHLN-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 101150020251 NR13 gene Proteins 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 238000011672 OFA rat Methods 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 102100036061 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Human genes 0.000 description 1
- 101710125691 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010045717 Proto-Oncogene Proteins c-akt Proteins 0.000 description 1
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- 238000003477 Sonogashira cross-coupling reaction Methods 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 101150057615 Syn gene Proteins 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- APWPIIIDXNQVPS-UHFFFAOYSA-N [6-chloro-5-phenyl-7-(trifluoromethoxy)-1h-indazol-3-yl]urea Chemical compound C1=C2C(NC(=O)N)=NNC2=C(OC(F)(F)F)C(Cl)=C1C1=CC=CC=C1 APWPIIIDXNQVPS-UHFFFAOYSA-N 0.000 description 1
- VYEYJCBEXFTGBN-UHFFFAOYSA-N acetic acid;1,3-dimethyl-7h-purine-2,6-dione Chemical compound CC(O)=O.O=C1N(C)C(=O)N(C)C2=C1NC=N2 VYEYJCBEXFTGBN-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 238000006254 arylation reaction Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 150000001638 boron Chemical class 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 235000020226 cashew nut Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000007336 electrophilic substitution reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-N iodic acid Chemical class OI(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- HCHCRJPKTMUOCM-UHFFFAOYSA-N n-(6-chloro-7-fluoro-5-phenyl-1h-indazol-3-yl)-1-methylimidazole-4-sulfonamide;n-(6-chloro-7-fluoro-5-phenyl-1h-indazol-3-yl)-1-phenylmethanesulfonamide Chemical compound CN1C=NC(S(=O)(=O)NC=2C3=CC(=C(Cl)C(F)=C3NN=2)C=2C=CC=CC=2)=C1.N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NS(=O)(=O)CC1=CC=CC=C1 HCHCRJPKTMUOCM-UHFFFAOYSA-N 0.000 description 1
- UKYWIKNIISMJTR-UHFFFAOYSA-N n-(6-chloro-7-fluoro-5-phenyl-1h-indazol-3-yl)-4-(trifluoromethyl)benzenesulfonamide Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NS(=O)(=O)C1=CC=C(C(F)(F)F)C=C1 UKYWIKNIISMJTR-UHFFFAOYSA-N 0.000 description 1
- DVRDILWFWFFCIU-UHFFFAOYSA-N n-(6-chloro-7-fluoro-5-phenyl-1h-indazol-3-yl)-4-fluorobenzenesulfonamide Chemical compound C1=CC(F)=CC=C1S(=O)(=O)NC1=NNC2=C(F)C(Cl)=C(C=3C=CC=CC=3)C=C12 DVRDILWFWFFCIU-UHFFFAOYSA-N 0.000 description 1
- KRFUZTMVCVSGOE-UHFFFAOYSA-N n-(6-chloro-7-fluoro-5-phenyl-1h-indazol-3-yl)methanesulfonamide;n-(6-chloro-7-fluoro-5-phenyl-1h-indazol-3-yl)-4-methylbenzenesulfonamide Chemical compound C1=C2C(NS(=O)(=O)C)=NNC2=C(F)C(Cl)=C1C1=CC=CC=C1.C1=CC(C)=CC=C1S(=O)(=O)NC1=NNC2=C(F)C(Cl)=C(C=3C=CC=CC=3)C=C12 KRFUZTMVCVSGOE-UHFFFAOYSA-N 0.000 description 1
- FOWHLTVNVFUXGW-UHFFFAOYSA-N n-(6-chloro-7-fluoro-5-phenyl-1h-indazol-3-yl)propane-2-sulfonamide Chemical compound C1=C2C(NS(=O)(=O)C(C)C)=NNC2=C(F)C(Cl)=C1C1=CC=CC=C1 FOWHLTVNVFUXGW-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- DBQRPLKMEVLZCF-UHFFFAOYSA-N n-[6,7-difluoro-5-phenyl-1-(2-trimethylsilylethoxymethyl)indazol-3-yl]piperidine-1-carboxamide Chemical compound C12=CC(C=3C=CC=CC=3)=C(F)C(F)=C2N(COCC[Si](C)(C)C)N=C1NC(=O)N1CCCCC1 DBQRPLKMEVLZCF-UHFFFAOYSA-N 0.000 description 1
- NTECIKXMSGVIGP-UHFFFAOYSA-N n-benzyl-6-chloro-7-fluoro-5-phenyl-1h-indazol-3-amine;6-chloro-7-fluoro-n-[(4-methoxyphenyl)methyl]-5-phenyl-1h-indazol-3-amine Chemical compound N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NCC1=CC=CC=C1.C1=CC(OC)=CC=C1CNC1=NNC2=C(F)C(Cl)=C(C=3C=CC=CC=3)C=C12 NTECIKXMSGVIGP-UHFFFAOYSA-N 0.000 description 1
- KGIPCWNQTRQWEZ-UHFFFAOYSA-N n-butyl-6-chloro-7-fluoro-5-phenyl-1h-indazol-3-amine;n-(6-chloro-7-fluoro-5-phenyl-1h-indazol-3-yl)-3-methoxybenzenesulfonamide;1-(6-chloro-7-fluoro-5-phenyl-1h-indazol-3-yl)-3-phenylurea Chemical class C1=C2C(NCCCC)=NNC2=C(F)C(Cl)=C1C1=CC=CC=C1.N=1NC=2C(F)=C(Cl)C(C=3C=CC=CC=3)=CC=2C=1NC(=O)NC1=CC=CC=C1.COC1=CC=CC(S(=O)(=O)NC=2C3=CC(=C(Cl)C(F)=C3NN=2)C=2C=CC=CC=2)=C1 KGIPCWNQTRQWEZ-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 125000004355 nitrogen functional group Chemical group 0.000 description 1
- 125000005593 norbornanyl group Chemical group 0.000 description 1
- 125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- USISRUCGEISZIB-UHFFFAOYSA-N piperidin-3-one Chemical compound O=C1CCCNC1 USISRUCGEISZIB-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000004036 potassium channel stimulating agent Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- QGKLPGKXAVVPOJ-UHFFFAOYSA-N pyrrolidin-3-one Chemical compound O=C1CCNC1 QGKLPGKXAVVPOJ-UHFFFAOYSA-N 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- ALZJERAWTOKHNO-UHFFFAOYSA-M sodium;dodecyl sulfate;3-morpholin-4-ylpropane-1-sulfonic acid Chemical compound [Na+].OS(=O)(=O)CCCN1CCOCC1.CCCCCCCCCCCCOS([O-])(=O)=O ALZJERAWTOKHNO-UHFFFAOYSA-M 0.000 description 1
- OVYTZAASVAZITK-UHFFFAOYSA-M sodium;ethanol;hydroxide Chemical compound [OH-].[Na+].CCO OVYTZAASVAZITK-UHFFFAOYSA-M 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0215720 | 2002-12-12 | ||
| FR0215720A FR2848554A1 (fr) | 2002-12-12 | 2002-12-12 | Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant |
| US44463003P | 2003-02-04 | 2003-02-04 | |
| US60/444,630 | 2003-02-04 | ||
| PCT/FR2003/002634 WO2004062662A1 (fr) | 2002-12-12 | 2003-09-03 | Derives d'aminoindazoles et leur utilisation comme inhibiteurs de kinases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2006516266A JP2006516266A (ja) | 2006-06-29 |
| JP2006516266A5 JP2006516266A5 (https=) | 2006-10-19 |
| JP4764168B2 true JP4764168B2 (ja) | 2011-08-31 |
Family
ID=32338720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005512867A Expired - Fee Related JP4764168B2 (ja) | 2002-12-12 | 2003-09-03 | アミノインダゾール誘導体及びキナーゼ阻害剤としてのその使用 |
Country Status (11)
| Country | Link |
|---|---|
| JP (1) | JP4764168B2 (https=) |
| CN (2) | CN1713909A (https=) |
| AR (1) | AR041132A1 (https=) |
| AT (1) | ATE520399T1 (https=) |
| FR (1) | FR2848554A1 (https=) |
| ME (1) | MEP25308A (https=) |
| MY (1) | MY138085A (https=) |
| PE (2) | PE20040996A1 (https=) |
| RS (1) | RS20050421A (https=) |
| TW (1) | TWI345561B (https=) |
| ZA (1) | ZA200504681B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007002717A1 (de) | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Heterocyclische Indazolderivate |
| DE102007022565A1 (de) | 2007-05-14 | 2008-11-20 | Merck Patent Gmbh | Heterocyclische Indazolderivate |
| ES2439773T3 (es) * | 2009-02-26 | 2014-01-24 | Glaxo Group Limited | Derivados de pirazol usados como antagonistas del receptor CCR4 |
| CA2989519C (en) | 2015-06-15 | 2023-09-26 | Ube Industries, Ltd. | Substituted dihydropyrrolopyrazole derivative |
| CN115260165B (zh) * | 2021-04-29 | 2024-08-06 | 中国科学院上海药物研究所 | 苯并含氮五元杂环化合物及其合成和应用 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS51143010A (en) * | 1975-06-04 | 1976-12-09 | Kao Corp | Stable bleaching detergent composition |
| WO2002022601A1 (en) * | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| WO2002074388A1 (en) * | 2001-03-19 | 2002-09-26 | Icagen, Inc. | Bisarylamines as potassium channel openers |
| WO2003028720A1 (en) * | 2001-09-26 | 2003-04-10 | Pharmacia Italia S.P.A. | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| WO2003078403A2 (fr) * | 2002-03-11 | 2003-09-25 | Aventis Pharma S.A. | Derives d’aminoindazoles comme inhibiteurs de proteine-kinase |
| WO2004022544A1 (fr) * | 2002-09-05 | 2004-03-18 | Aventis Pharma S.A. | Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant |
-
2002
- 2002-12-12 FR FR0215720A patent/FR2848554A1/fr active Pending
-
2003
- 2003-09-01 PE PE2003000886A patent/PE20040996A1/es not_active Application Discontinuation
- 2003-09-01 PE PE2009001071A patent/PE20091629A1/es not_active Application Discontinuation
- 2003-09-03 AR ARP030103187A patent/AR041132A1/es unknown
- 2003-09-03 CN CNA038256169A patent/CN1713909A/zh active Pending
- 2003-09-03 JP JP2005512867A patent/JP4764168B2/ja not_active Expired - Fee Related
- 2003-09-03 CN CN2010105043043A patent/CN101979382A/zh active Pending
- 2003-09-03 ME MEP-253/08A patent/MEP25308A/xx unknown
- 2003-09-03 RS YUP-2005/0421A patent/RS20050421A/sr unknown
- 2003-09-03 AT AT03769560T patent/ATE520399T1/de not_active IP Right Cessation
- 2003-09-04 TW TW092124409A patent/TWI345561B/zh not_active IP Right Cessation
- 2003-09-04 MY MYPI20033346A patent/MY138085A/en unknown
-
2005
- 2005-06-08 ZA ZA200504681A patent/ZA200504681B/en unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS51143010A (en) * | 1975-06-04 | 1976-12-09 | Kao Corp | Stable bleaching detergent composition |
| WO2002022601A1 (en) * | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| WO2002074388A1 (en) * | 2001-03-19 | 2002-09-26 | Icagen, Inc. | Bisarylamines as potassium channel openers |
| WO2003028720A1 (en) * | 2001-09-26 | 2003-04-10 | Pharmacia Italia S.P.A. | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| WO2003078403A2 (fr) * | 2002-03-11 | 2003-09-25 | Aventis Pharma S.A. | Derives d’aminoindazoles comme inhibiteurs de proteine-kinase |
| WO2004022544A1 (fr) * | 2002-09-05 | 2004-03-18 | Aventis Pharma S.A. | Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant |
Also Published As
| Publication number | Publication date |
|---|---|
| PE20040996A1 (es) | 2005-01-28 |
| CN1713909A (zh) | 2005-12-28 |
| TWI345561B (en) | 2011-07-21 |
| TW200422293A (en) | 2004-11-01 |
| JP2006516266A (ja) | 2006-06-29 |
| RS20050421A (sr) | 2007-08-03 |
| AR041132A1 (es) | 2005-05-04 |
| PE20091629A1 (es) | 2009-11-16 |
| ATE520399T1 (de) | 2011-09-15 |
| CN101979382A (zh) | 2011-02-23 |
| MY138085A (en) | 2009-04-30 |
| MEP25308A (en) | 2010-06-10 |
| ZA200504681B (en) | 2006-08-30 |
| FR2848554A1 (fr) | 2004-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7407981B2 (en) | Aminoindazole derivatives as medicaments and pharmaceutical compositions including them | |
| JP5171918B2 (ja) | キナーゼ阻害剤として有用なアミノインダゾール誘導体を合成するための中間体化合物 | |
| RU2345070C2 (ru) | Производные аминоиндазолов в качестве лекарственных средств, способ их получения и содержащие их фармацевтические композиции | |
| JP4764168B2 (ja) | アミノインダゾール誘導体及びキナーゼ阻害剤としてのその使用 | |
| TWI353978B (en) | Novel aminoindazole derivatives as medicaments and |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060830 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060830 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100518 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100818 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101116 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110216 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110223 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110328 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110422 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110517 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110610 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140617 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |